# Ablexis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ablexis

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.ablexis.com
- Total disclosed funding: $12M
- Latest round: Series A (Jun 2, 2010)
- Investors on record: 2

## About

Ablexis, LLC is a biotechnology firm focused on advanced antibody discovery using a proprietary transgenic mouse platform, which streamlines the development of therapeutic antibodies for pharmaceutical and biotechnology companies.Ablexis, LLC is engaged in developing a transgenic mouse platform designed for therapeutic antibody discovery. The company is headquartered in San Francisco, US. Larry Green is the founder and CEO, bringing experience from prior ventures in the biotech sector. In June 2010, Ablexis raised USD 12 mn in Series A funding, led by Third Rock Ventures and joined by Pfizer Venture Investments, which constitutes their total amount raised.Ablexis specializes in a next-generation transgenic mouse platform designed specifically for the discovery of therapeutic antibodies. Their core product, the AlivaMab-X Mouse, is engineered to deliver enhanced immune responses, facilitating a more efficient antibody discovery process. The platform is utilized primarily by biotechnology and pharmaceutical companies engaged in developing novel therapeutics, aiming to address critical healthcare needs. Their customer base spans North America, Europe, and Asia, targeting research institutions and companies focused on immunotherapy and other antibody-based treatments.Ablexis operates on a revenue model structured around partnerships and licensing agreements with biopharmaceutical companies. Clients engage with Ablexis through tailored licensing options that allow them to integrate the AlivaMab-X Mouse platform into their research and development workflows. Transactions typically involve upfront licensing fees coupled with milestone payments tied to the progress of therapeutics developed using their technology, reflecting the value provided through their transgenic platform and benefiting clients by reducing time and costs associated with traditional antibody discovery methods.Ablexis plans to utilize the USD 12 mn raised in the Series A round to further develop their transgenic mouse technology and expand their market presence. The company seeks to introduce enhancements to the AlivaMab-X Mouse platform by late 2021, targeting biotechnology firms in emerging markets, particularly in Asia and Europe. The focus will be on increasing partnerships with research institutions while enhancing the capabilities of their existing offerings, ensuring alignment with the growing demand for innovative therapeutic solutions.

## Funding rounds

- Series A, Jun 2, 2010, $12M — Third Rock Ventures, Pfizer Venture Investments

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A